论文部分内容阅读
FDA批准EffientTM(prasugrel)片剂用于减少接受名为经皮冠脉介入(PCI)治疗的动脉扩张手术治疗的急性冠脉综合征患者的血栓形成心血管事件(包括固定膜血栓形成)的发生。该批准基于代号为TRITON-TIMI38的Ⅲ期关键性试验数据。数据表明多种不同类型患者接受prasugrel治疗后,因心血
FDA approved Effient ™ (prasugrel) tablets to reduce the occurrence of thrombotic cardiovascular events (including fixed-membrane thrombosis) in patients with acute coronary syndrome who underwent arterial dilatation surgery called percutaneous coronary intervention (PCI) . The approval is based on Phase III pivotal trial data codenamed TRITON-TIMI38. Data show that many different types of patients after receiving prasugrel treatment due to blood